Shots: The NDA is based on two clinical studies, P-III CELESTIAL (XL184-309) & P-II Cabozantinib-2003 study assessing Cabometyx in patients with advanced HCC prior treated with systemic therapy In 2017, […]readmore
Tags : Advanced Hepatocellular Carcinoma
Shots: The US FDA has accepted sBLA and granted BT designation for the dual regimen to treat patients with advanced HCC prior treated with sorafenib. The sBLA ha also received […]readmore
Shots: The P-III KEYNOTE-240 Study involves assessing of Keytruda (200mg, q3w) vs PBO in 413 patients with 1L advance HCC The study resulted in unmet 1EPs & 2EPs as OS, […]readmore